Proactive Investors - Run By Investors For Investors

Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option

The AIM-listed group said the decision by Deinove follows a period of nine months of evaluation during which it had sole rights to develop the Novel Bacterial Topoisomerase Inhibitor programme
Drug testing
It added that all rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx

Redx Pharma Plc (LON:REDX) is exploring options for Novel Bacterial Topoisomerase Inhibitor (NBTI) programme with other parties potentially interested in licensing the project after Deinove said it has decided not to exercise their option.

The AIM-listed drug discovery and development company focused on cancer and fibrosis said the decision by Deinove follows a period of nine months of evaluation during which the group had sole rights to develop the programme.

WATCH: Redx Pharma receives approval to re-commence clinical trial of RXC004

The group added that all rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx.

The firm entered into an option and license agreement with Deinove for the NBTI programme in March 2018 following a strategic decision to close the Redx anti-infectives unit in 2017, and focus on developing new medicines in Oncology and Fibrosis. 

Last week, Redx announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval to the company to re-commence the phase 1/2a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway.

It said clinical evaluation of RXC004 in patients with advanced solid tumours remains on track to resume in H1 2019 following the approval of a revised phase 1/2a clinical trial protocol and drug formulation.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
salmon
January 31 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use